| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/23/2001 | US6177074 Polyethylene glycol modified interferon therapy |
| 01/23/2001 | US6177059 Drugs and complexes with lipids |
| 01/23/2001 | CA2296884C Targeted liposomes and methods for liposome-protein coupling |
| 01/23/2001 | CA2221767C A peptide inhibiting elevations of triglyceride levels in blood and an agent for inhibiting elevations of triglyceride levels in blood comprising the peptide as an active component |
| 01/23/2001 | CA2188871C Method for treating psoriasis |
| 01/22/2001 | CA2746824A1 Neurotherapeutic composition and method |
| 01/22/2001 | CA2313392A1 Agent for induction of antigen-specific t cell |
| 01/18/2001 | WO2001004629A1 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
| 01/18/2001 | WO2001004354A2 Use of ras inhibitors of inhibiting muscle atrophy |
| 01/18/2001 | WO2001004349A2 Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease |
| 01/18/2001 | WO2001004344A2 Induction of a th1-like response in vitro |
| 01/18/2001 | WO2001004329A1 Modified human granulocyte-colony stimulating factor and process for producing same |
| 01/18/2001 | WO2001004328A1 Chlamysin b antibacterial protein, gene encoding it and an expression system for it |
| 01/18/2001 | WO2001004326A1 Tankyrase homolog protein (thp), nucleic acids, and methods related to the same |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004317A1 Ompa gene for an outer membrane protein of riemerella anatipestifer and methods of use |
| 01/18/2001 | WO2001004316A2 Antigenic meningococcal peptides |
| 01/18/2001 | WO2001004312A1 Proliferation differentiation factor |
| 01/18/2001 | WO2001004309A1 T-CELL RECEPTOR η ALTERNATE READING FRAME PROTEIN, (TARP) AND USES THEREOF |
| 01/18/2001 | WO2001004308A1 Human lim domain proteins |
| 01/18/2001 | WO2001004305A2 Human proteins involved in detoxification |
| 01/18/2001 | WO2001004304A1 Human cytokine receptor |
| 01/18/2001 | WO2001004302A1 Atopy gene |
| 01/18/2001 | WO2001004301A1 Fatty acid transporter protein and gene encoding the protein |
| 01/18/2001 | WO2001004300A1 Apoptosis-associated factor |
| 01/18/2001 | WO2001004299A1 AMYLOID β PROTEIN AGGLUTINATION CONTROLLING FACTOR |
| 01/18/2001 | WO2001004297A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 01/18/2001 | WO2001004296A1 Rbp1 polypeptides and uses thereof |
| 01/18/2001 | WO2001004295A1 Orbit and homologues thereof |
| 01/18/2001 | WO2001004294A1 Antimicrobial peptides derived from molluscs |
| 01/18/2001 | WO2001004290A1 Triplex-forming oligonucleotides and their use in therapy |
| 01/18/2001 | WO2001004281A2 Dna coding for beta-tubulin and use thereof |
| 01/18/2001 | WO2001004266A1 A lung cancer associated retrovirus, gene delivery vector and methods of use thereof |
| 01/18/2001 | WO2001004264A2 Atherosclerosis-associated genes |
| 01/18/2001 | WO2001004160A1 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines |
| 01/18/2001 | WO2001004157A2 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 01/18/2001 | WO2001004156A1 Peptides that lower blood glucose levels |
| 01/18/2001 | WO2001004155A2 Feline interleukin-12 as an immune stimulant |
| 01/18/2001 | WO2001004146A2 Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof |
| 01/18/2001 | WO2001004145A2 Glutx polypeptide family and nucleic acids encoding same |
| 01/18/2001 | WO2001004139A2 Human axor29 receptor |
| 01/18/2001 | WO2001004133A1 Human eag2 |
| 01/18/2001 | WO2001003821A1 Method of particle formation |
| 01/18/2001 | WO2001003743A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | WO2001003741A1 Growth hormone formulations |
| 01/18/2001 | WO2001003740A1 Serine protease inhibitor |
| 01/18/2001 | WO2001003737A1 Immunoglobulin fusion proteins |
| 01/18/2001 | WO2001003728A2 Gene therapy for enhancing and/or inducing angiogenesis |
| 01/18/2001 | WO2001003727A1 Novel methods and medicament for treating infectious diseases involving microbial biofilms |
| 01/18/2001 | WO2001003726A1 Stable factor viii compositions |
| 01/18/2001 | WO2001003725A1 Use of interleukin-6 in treatment of obesity and/or obesity associated disorders |
| 01/18/2001 | WO2001003724A1 Therapeutic uses of bpi protein products for inhibiting h+/k+ atpase activity |
| 01/18/2001 | WO2001003723A1 Hybrid polypeptides with enhanced pharmacokinetic properties |
| 01/18/2001 | WO2001003722A1 Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing |
| 01/18/2001 | WO2001003720A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | WO2001003719A2 Combination therapy for conditions leading to bone loss |
| 01/18/2001 | WO2001003718A2 Combination chemotherapy |
| 01/18/2001 | WO2001003717A2 Methods of inducing cell death |
| 01/18/2001 | WO2001003716A1 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 01/18/2001 | WO2001003710A1 Analgesic from snake venom |
| 01/18/2001 | WO2001003708A1 Cadmium containing compositions |
| 01/18/2001 | WO2001003692A1 Compositions and methods for promoting nerve regeneration |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2001003686A2 Inhibitors of staphylococcus sara protein and their use in treating staphylococcal infections |
| 01/18/2001 | WO2001003673A1 Dry powder compositions |
| 01/18/2001 | WO2001003670A1 Method for controlled production of ultrafine microparticles and nanoparticles |
| 01/18/2001 | WO2001003667A1 Delivery system for biological material |
| 01/18/2001 | WO2000071714A3 Methods of reducing factor viii clearance and compositions therefor |
| 01/18/2001 | WO2000068383A3 Family of immunoregulators designated leukocyte immunoglobulin-like receptors (lir) |
| 01/18/2001 | WO2000066620A3 Morphogen-induced enhancement of fertility |
| 01/18/2001 | WO2000063378A3 Zalpha13: a human secreted protein |
| 01/18/2001 | WO2000063234A3 Pyrrolidincarbonylamino cyclic disulfides as vcam-vla4 antagonists |
| 01/18/2001 | WO2000062793A3 Pseudomycin antifungal compositions and methods for their use |
| 01/18/2001 | WO2000062744A3 Skin care compositions containing combination of skin care actives |
| 01/18/2001 | WO2000062743A3 Skin care compositions containing combination of skin care actives |
| 01/18/2001 | WO2000061786A3 Antisense modulation of pdk-1 expression |
| 01/18/2001 | WO2000061752A3 Modified complement system regulators |
| 01/18/2001 | WO2000060078A3 Latheo encodes a subunit of the origin of recognition complex |
| 01/18/2001 | WO2000060050A3 Recombinant influenza viruses for vaccines and gene therapy |
| 01/18/2001 | WO2000059531A3 Therapeutic uses of bpi protein products in bpi-deficient humans |
| 01/18/2001 | WO2000056864A3 Methods for altering substrate specificity of phosphoinositide-dependent-protein kinase 1 (pdk1) |
| 01/18/2001 | WO2000055193A3 Human dan/cerberus related protein 6 (dcr6) |
| 01/18/2001 | WO2000055180A3 Human lung cancer associated gene sequences and polypeptides |
| 01/18/2001 | WO2000053774A3 Metalloproteinases and methods of use therefor |
| 01/18/2001 | WO2000053213A3 Cyanovirin conjugates, matrix-anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use |
| 01/18/2001 | WO2000051631A3 Pegylated alpha interferon for hiv therapy |
| 01/18/2001 | WO2000051630A3 Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent |
| 01/18/2001 | WO2000047723A3 Human diacylglycerol kinase beta (hdagk beta) proteins and nucleotide sequences encoding the same |
| 01/18/2001 | WO2000040227A3 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 01/18/2001 | WO2000039304A3 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/18/2001 | WO2000037634A3 Novel polypeptides and nucleic acids encoding same |
| 01/18/2001 | WO2000037067A3 Sensitizing agents for the treatment of skin lesions |
| 01/18/2001 | WO2000035492A3 Vitronectin receptor antagonist pharmaceuticals |
| 01/18/2001 | WO2000032825A3 Development of anti-microbial agents based on bacteriophage genomics |
| 01/18/2001 | WO2000023565B1 Novel neuropilin/growth factor binding and uses thereof |
| 01/18/2001 | WO2000002911A3 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) |
| 01/18/2001 | WO1999064049A9 Novel antibacterial agents |
| 01/18/2001 | WO1999050403A3 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses |
| 01/18/2001 | DE19933492A1 Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen Conjugate to the presentation of cell-, or compartment-specific membrane transport of active substances |
| 01/18/2001 | DE19933288A1 Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung Structural protein of adeno-associated virus with altered antigenicity, its preparation and use |